Overview

M8891 First in Human in Solid Tumors

Status:
Active, not recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD), safety, tolerability, Pharmacokinetic (PK), pharmacodynamic and clinical activity of M8891 as single agent in participants with advanced solid tumors in Part 1 and to determine the safety, tolerability, PK and antitumor activity of M8891 combined with cabozantinib in participants with metastatic renal cell carcinoma (mRCC) in Part 2 (Part 2a and Part 2b) of the study.

Phase:

Phase 1

Details

Lead Sponsor:

EMD Serono Research & Development Institute, Inc.

Collaborators:

Merck KGaA
Merck KGaA, Darmstadt, Germany